A total of 439 patients with untreated advanced or metastatic NSCLC treated with PD‐1 blockade combined with chemotherapy or chemotherapy alone were identified for eligibility in this study (Figure 1). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.